VAS third-line eradication study

JRCT ID: jRCTs031190031

Registered date:27/05/2019

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Helicobacter pylori infection
• Date of first enrollment: 17/06/2019
• Target sample size: 68
• Study type: Interventional
• Intervention(s): sitafloxacin (100mg)+amoxicillin (750mg)+Vonoprazan (20mg) given on twice daily for 7days

Outcome(s)

• Primary Outcome: Eradication rate
• Secondary Outcome: Adverse event by questionnaire

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both
• Include criteria: First line eradication(PPI+AMPC+CAM) and second line eradication(PPI+AMPC+MNZ) failure patients with H.pylori infection who want to take eradication treatment. Patients who give a written informed consent.
• Exclude criteria: Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Severe liver dysfunction, Severe renal dysfunction, Severe heart dysfunction. Patients who are disqualified for the study by physicians.

Related Information

• Primary Sponsor: Soichiro Sue
• Source(s) of Monetary Support: Yokohama City University